What is it about?
The cytosolic phospholipase A2 is a cellular enzyme that appears to be at the center of pathological pathways leading to Alzheimer's disease due to its increased activity. Our therapeutic agent was designed to accede to the brain enzyme and diminish its activity. This has led to the attenuation of molecular burden in a mouse model of Alzheimer's disease and the improvement of cognitive abilities.
Featured Image
Photo by Clément Falize on Unsplash
Why is it important?
Alzheimer’s disease is lacking any curative treatment up to now, and actual medication given to the patients alleviates only symptoms. None of the therapeutic strategies proposed up to date gave convincing results, and the Alzheimer’s disease therapy remains a real challenge. In this context, the modulation of cytosolic phospholipase A2 with our pharmacological agent could be a promising therapeutic strategy for Alzheimer’s disease.
Perspectives
An extensive pharmacological characterization is required to attest to non-toxicological effects and the therapeutic efficacy our therapeutic strategy.
Professor Carmen Burtea
University of Mons
Read the Original
This page is a summary of: Modulation of Cytosolic Phospholipase A2 as a Potential Therapeutic Strategy for Alzheimer’s Disease, Journal of Alzheimer s Disease Reports, December 2023, IOS Press,
DOI: 10.3233/adr-230075.
You can read the full text:
Contributors
The following have contributed to this page
